Vitexin protects against cardiac hypertrophy via inhibiting calcineurin and CaMKII signaling pathways

Author： Lu Cui-cui Xu Ying-qi Wu Ji-chao Hang Peng-zhou Wang Yan Wang Chen Wu Jian-wei Qi Jian-cui Zhang Yong Du Zhi-min

Publisher： Springer Publishing Company

ISSN： 0028-1298

Source： Naunyn-Schmiedeberg's Archives of Pharmacology, Vol.386, Iss.8, 2013-08, pp. : 747-755

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Targeting calcineurin and associated pathways in cardiac hypertrophy and failure

By Fiedler Beate Wollert Kai C

Expert Opinion on Therapeutic Targets, Vol. 9, Iss. 5, 2005-10 ,pp. : 963-973

Informa Healthcare

Access to resources Recommend Favorite

Tanshinone IIA protects rat primary hepatocytes against carbon tetrachloride toxicity via inhibiting mitochondria permeability transition

By Zhu Bin Zhai Qing Yu Bo

Pharmaceutical Biology (Formerly International Journal of Pharmacognosy), Vol. 48, Iss. 5, 2010-05 ,pp. : 484-487

Informa Healthcare

Access to resources Recommend Favorite

Jatrorrhizine Protects Against Okadaic Acid Induced Oxidative Toxicity Through Inhibiting the Mitogen-Activated Protein Kinases Pathways in HT22 Hippocampal Neurons

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 14, Iss. 10, 2015-12 ,pp. : 1334-1342

Bentham Science Publishers

Access to resources Recommend Favorite

The promise of CaMKII inhibition for heart disease: preventing heart failure and arrhythmias

By Westenbrink B Daan

Expert Opinion on Therapeutic Targets, Vol. 17, Iss. 8, 2013-08 ,pp. : 889-903

Informa Healthcare

Access to resources Recommend Favorite

Experimental Antiarrhythmic Targets: CaMKII Inhibition – Ready for Clinical Evaluation?

Current Medicinal Chemistry, Vol. 21, Iss. 11, 2014-04 ,pp. : 1299-1307

Bentham Science Publishers

Access to resources Recommend Favorite